Additionally, PLK1 Other mutations might be associated with higher prevalence of mutated cell cycle pathway in both NSCLC and CRC, particularly in comparison to PLK1 PB1 mutations (p < 0.001, Figure 1E). This evidence concerns the gene PLK1 and non-small cell lung carcinoma.